The peptide AF-16 and the AF protein counteract intracranial hypertension

8Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Intracranial hypertension develops after, for example, trauma, stroke and brain inflammation, and contributes to increased morbidity, mortality, and persistent neuropsychiatric sequelae. Nonsurgical therapy offers limited relief. We investigated whether the peptide AF-16 and the endogenous protein Antisecretory Factor (AF) counteracted abnormal fluid transfer by cells, and lowered raised intracranial pressure (ICP). Adult rats, infected with an encephalitogenic Herpes simplex virus (HSV-1), developed after 5 days' sickness of increasing severity. AF-16 rescued all rats while vehicle treatment only saved 20%. AF-16 from day 4 reduced the ICP in HSV-1-infected rats from 30.7 to 14.6 mmHg and all survived without sequelae. A standardised closed head brain injury in rats raised the ICP. Continuous and intermittent AF-16 kept ICP at an almost normal level. A single dose of AF-16 maintained the raised ICP after a TBI lowered during 3-9 h. The AF protein, enriched in egg yolk, similarly lowered the post-traumatically raised ICP in rats. AF-16 also lowered the ICP in rabbits with diffuse brain injury. We conclude that the peptide AF-16 and the AF protein offer new approaches to treat raised ICP with no side effects. © 2012 Springer-Verlag/Wien.

Cite

CITATION STYLE

APA

Hansson, H. A., Al-Olama, M., Jennische, E., Gatzinsky, K., & Lange, S. (2012). The peptide AF-16 and the AF protein counteract intracranial hypertension. In Acta Neurochirurgica, Supplementum (Vol. 114, pp. 377–382). Springer-Verlag Wien. https://doi.org/10.1007/978-3-7091-0956-4_73

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free